Vincristine sulfate

目录号：S1241 别名： Leurocristine

Molecular Weight(MW): 923.04

Vincristine sulfate通过与微管蛋白结合而抑制微管聚合，IC50为32 μM。

规格

价格

库存

购买数量

10mg	RMB 582.05	现货
50mg	RMB 2229.59	现货
200mg	RMB 7118.45	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献14篇：

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

J Pharmacol Exp Ther, 2014, 350(3):646-56

PubMed: 24993360 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):10736-49

PubMed: 23109819 ( click the link to review the publication )

Lipids Health Dis, 2016, 15:152

PubMed: 27613245 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1965

PubMed: 30530705 ( click the link to review the publication )

Leukemia, 2018, 32(3):616-625

PubMed: 28904384 ( click the link to review the publication )

Chemosphere, 2018, 210:467-475

PubMed: 30025364 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Cell Death & Disease, 2017, 10.1038/cddis.2017.454

PubMed: ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1335-1351

PubMed: 28496304 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2017, 18(1):63

PubMed: 28877739 ( click the link to review the publication )
Mol Cancer Res, 2016, 14(10):909-919

PubMed: 27358112 ( click the link to review the publication )

Cell Rep, 2015, 13(11):2353-2361

PubMed: 26686626 ( click the link to review the publication )

客户使用该产品的2个实验数据：

Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent experiments and of f our replicates in each experiment.

Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

产品安全说明书

Microtubule Associated抑制剂选择性比较

生物活性

产品描述

Vincristine sulfate通过与微管蛋白结合而抑制微管聚合，IC50为32 μM。

靶点

Microtubules ^[1]
(Cell-free assay)

32 μM

体外研究

Vincristine抑制微管蛋白二聚体聚合亚单位,抑制它们的聚合作用，K_i为85 nM。^[1]在低浓度时，Vincristine抑制纺锤体，使染色体分离失败，进而导致中期停滞，并抑制有丝分裂。在较高浓度时，Vincristine可能干扰且诱导全部微管解聚。^[2] Vincristine 诱导肿瘤细胞凋亡，且抑制SH-SY5Y细胞增殖，IC50为0.1 µM。Vincristine诱导有丝分裂停滞，促进caspase-3和-9及cyclin B的表达，但降低cyclin D的表达。^[3] Vincristine通过干扰微管功能而诱导神经毒性形成，这会导致轴突运输堵塞，从而导致轴突变性。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HepG2.2.15	NYnldpRuS2WubDDWbYFjcWyrdImgRZN{[Xl?	MlHPNE0xNjVizszN	NIrpTJAzPCCq		MWTk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	MXuyOVY3Ozd4OR?=
HepG2-HBV1.1	NVrySYQ1SXCxcITvd4l{KEG\|c3H5	MnPDNE0xNjVizszN	MUSyOEBp		M1K2VYlv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm=	MoOzNlU3PjN5Nkm=
HepG2.2.15	M4S0TGZ2dmO2aX;uJGF{e2G7	NF34cFMxNjFizszN	MkHJNlQhcA>?		Mk[3dJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO\|aX;u	MXOyOVY3Ozd4OR?=
HepG2-HBV1.1	MnPMSpVv[3Srb36gRZN{[Xl?	MViwMlEh\|ryP	MXqyOEBp		MlXDdJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO\|aX;u	NU\zTWxZOjV4NkO3Olk>
HepG2-HBV1.1	NITlcotHfW6ldHnvckBCe3OjeR?=	MX[wMlEh\|ryP	NETPcpI1QCCq		NWD1cnZveHKxbX;0[ZMh[2WubDDlfINz\XSrb36gc4YhcGWyYYTpeIl{KEJidnnyeZMhdnWlbHXvZ4Fxe2mmczDpcpN1\WGmIH;mJIhmeGG2aYTpd{BDKH[rcoXzJGRidmVicHHyeIlkdGW\|	NYC3XmxNOjV4NkO3Olk>
HepG2-HBV1.1	MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DvN\|AvOSEQvF2=	NUfC[HV[OS13IHS=		NUTWUJNEcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=>	MoXnNlU3PjN5Nkm=
HepG2-HBV1.1	NFfsSolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWKySHA1OC5zIN88US=>	MYexMVUh\A>?		M1PrfIlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm=	MYqyOVY3Ozd4OR?=
HepG2-HBV1.1	M{fadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVf3XXJuOC5zIN88US=>	Mo\jNVIuPzJiaB?=		NVvNTlVicW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm	NY\UTYZGOjV4NkO3Olk>
HepG2-HBV1.1	NVXa[IVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWKwMlEh\|ryP	NHvyXmUyOi15MjDo		NV;YNZYycW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm	MlfvNlU3PjN5Nkm=
Raji	NYLLcW85TnWwY4Tpc44hSXO\|YYm=	NXTINmc5OC53wrFOwG0>	M1HqOlczKGh?		Mlv0ZYJwdGm\|aHXzJIF2fG:yaHHnfeKh	NHXVSZMzPTR2NkO3Oy=>
SK-MEL-28	NEPRU3dHfW6ldHnvckBCe3OjeR?=	NFzjOo0{OCCwTR?=	M2HHe\|YhcA>?		NXPLcY1JcW6mdXPld{BIOuLCk12gZ4VtdC2leXPs[UBienKnc4S=	MYCyOVMyOzBzMB?=
H157	M2rTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3SzWWlEPTB;MT6wN{DDuSByLkC0JI1qfTKP	M3nN[lI2OjV5OUGx
Jurkat	M4C4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml34NU0{KG6P	NUnsbodQPDkEoHi=	NGLwXZBFVVOR	NWXXTZJn\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>?	M2frT\|I2OTV4MUS2
CEM	M1nrdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXexMVMhdk1?	NX:4TXlFPDkEoHi=	NIDz[XhFVVOR	MY\k[YNz\WG\|ZYOgeoli[mynIHPlcIwhdnWvYnXyd{Bld3OnIHTldIVv\GWwdHz5	NFPwfGMzPTF3NkG0Oi=>
P12	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnW2NU0{KG6P	MYm0POKhcA>?	MYTEUXNQ	NWfNTGkz\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>?	M1HCc\|I2OTV4MUS2
KB	NWTSfIVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFj2fI9KSzVyPUCuNFA1QSEEsTCwMlAxODFizszN	MYCyOVA2QDV{Nh?=
KBv200 (ABCB1)	NWK1PY9wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTy[WRsUUN3ME2wMlM1PjJiwsGgNE4xODZ4IN88US=>	NHrwW5AzPTB3OEWyOi=>
SUDHL6	NHqxV\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTWWmhVOeLCid88US=>	MYC0PE84OiCq		MofibY5pcWKrdIOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=>	MnSwNlQ6PjF4MES=
SUDHL6	NUHNd5hFTnWwY4Tpc44hSXO\|YYm=	NFHUXW0y6oDLzszN	MUG3NkBp		M37t[olv\HWlZYOgd4lodmmoaXPhcpQh[XCxcITveIlkKG2xcoDoc4xw\3liY3jhcodmeyClb4Ty[ZN1\WRid3n0bEBDS0xzMVGgd4lTVkF?	Ml\FNlQ6PjF4MES=
HCT-116	M4rQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPIdG9pT0l3ME21JI5O	M3jZblI1QTJ5OEW3
SKNBe2C	NGq3PJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17NV2lEPTB;M{KuPOKyPC5yIH7N	NFrxZ2ozPDl{MUmyNC=>
IGNR91	NIDxU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDuTWM2OD1{ND6zxtEyNjdibl2=	NGjpcJIzPDl{MUmyNC=>
SKNAS	NED2[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTFwNdMxNE4zKG6P	MkXlNlQ6OjF7MkC=
LAN1	NWTxc3RRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTwTWM2OD1{LkRCtVAvOiCwTR?=	MnLCNlQ6OjF7MkC=
SHSY5Y	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzMd4pKSzVyPUiuNuKyOC54IH7N	M1[2flI1QTJzOUKw
A549-WT	NV6wRWlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\FSVY{UUN3ME2xPU41OzdiwsGgNE42QTRiIH7N	NEHGOGUzPDh3OEiyOy=>
A549-R	M1XrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTF{LkG3PEDDuSByLkOzN{Ahdk1?	MXGyOFg2QDh{Nx?=
MCF-7-WT	NEH1OYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnITWM2OD1zNz63OVIhyrFiMD6yNVghKG6P	M1vMNFI1QDV6OEK3
MCF-7-R	NFXKTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTBTWM2OD13LkWzPUDDuSByLkG0OEAhdk1?	NILHV\|IzPDh3OEiyOy=>
A549-R	NWnQTm1MS3m2b4TvfIlkcXS7IFHzd4F6				NIq2bVJKSzVyPUGyMlE4QCEEsTCwMlM{OyCwTR?=	MXOyOFg2QDh{Nx?=
MCF-7-R	Mn7FR5l1d3SxeHnjbZR6KEG\|c3H5				M2TtPGlEPTB;NT61N\|khyrFiMD6xOFQhdk1?	NFnKXVQzPDh3OEiyOy=>
SW620	NVLB[I5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLCTWM2OD15LkiwJOKyKDBwMEigcm0>	M4XHSVI1PzJ4N{O5
SW620/AD300	NH;wb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfLTWM2OD17MEmuOlAhyrFiOD65NUBvVQ>?	NIrMUlUzPDd{NkezPS=>
HEK293/pcDNA3.1	NEHBWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPWbGxKSzVyPUGuOFUhyrFiMD6yNEBvVQ>?	MVOyOFczPjd\|OR?=
HEK293/ABCC1	M3PxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTF7LkK5JOKyKDJwMEigcm0>	M{PJ[lI1PzJ4N{O5
TCC	NXvvbWx6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkHHNlQhcA>?		M2C3N2lEPTB;N{Cgcm0>	M2j3TVI1PzF4OUS0
TCC	NWO3UpJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGLKOoo1QCCq		NGm1NJFKSzVyPUWwJI5O	NIjiV28zPDdzNkm0OC=>
HepG2/ADM	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fZ[mlEPTB;Mj63PFY{yrFyLkKzO\|Eh\|ryP	NHPhcIYzPDdyNEW1Oi=>
HepG2	NVzCO49wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7RTWM2OD1yLkCxNVXDuTBwMECxO{DPxE1?	MXuyOFcxPDV3Nh?=
MCF-7/ADR	MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jiRmlEPTB;ND60PFI3yrFyLkKwO\|Ah\|ryP	NUjQTZlpOjR5MES1OVY>
MCF-7	MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVq5UpgyUUN3ME2wMlAyPToEsUCuNFA3OiEQvF2=	NEjFS3QzPDdyNEW1Oi=>
A-172	M3fXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHJb3kxNjIEoN88US=>	NXLI[YxJOjRxN{KgbC=>		NHPyfpRqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6	NWfmb2R4OjR3M{CyN\|U>
U-251MG	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfxZ5ZKOC5zwrFOwG0>	MVeyOE84OiCq		MkjKbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=>	NISyfFYzPDV\|MEKzOS=>
DLD-1	MnfYSpVv[3Srb36gRZN{[Xl?	M3XqeVExOCCwTR?=	NHHFTJQ1QCCq		MkHudJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh	M{jMWVI1PDB\|NEWz
CCD18Co	NYnKOJBMTnWwY4Tpc44hSXO\|YYm=	NYnLbI1kOTByIH7N	M1iyOVQ5KGh?		MoixdJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh	M33qUVI1PDB\|NEWz
DLD-1	M3;TU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXmwMVExODBibl2=	NYq1Wpl4PDhiaB?=		NX32WGJNcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>?	NXf1OYd1OjR2MEO0OVM>
CCD18Co	NXXUOIVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVWwMVExODBibl2=	MlLDOFghcA>?		MoizbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	NFe2WWEzPDRyM{S1Ny=>
HepG2	MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXG4WVhSOjRiaB?=		NWjGVlY{UUN3ME21Nk426oDLzszN	M4H3[VI1OzRzNki4
HEK293/pcDNA3.1	NY\RWGdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTBwMEC0xtExNjByMEOg{txO	MmjGNlQzQDR5OEO=
HEK293/MRP1	NEXJfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;nR2FKSzVyPUCuNFU2yrFyLkCxNlAh\|ryP	M13nSlI1Ojh2N{iz
Ramos	MYTBdI9xfG:\|aYOgRZN{[Xl?	NX7xPJJWOuLCid88US=>	MojPOFghcA>?		MoO0bY5lfWOnczCzOE43LcLzMT65NkUh[XCxcITvd4l{	MYGyOFI2PjR7MR?=
NCI-H1299/pcDNA3	M2O1PGNmdGxiVnnhZoltcXS7IFHzd4F6	MU[wMVIxKG6P	NXPoOYJSQTZiaB?=		NULwepRlcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	NEO0NW4zPDF5N{CxNi=>
H1299/ICAM-3	M{KwR2NmdGxiVnnhZoltcXS7IFHzd4F6	NESxOmkxNTJyIH7N	M{nxelk3KGh?		NUfMUJp2cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	Mn7WNlQyPzdyMUK=
NCI-H1299/pcDNA3	NFvJTJVHfW6ldHnvckBCe3OjeR?=	M{\uZ\|EwPS9zMD:yNOKhdk1?	NFe1[Hg6PiCq		M2D0N4lv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[ZMuOyxiODygPUwh[W6mIGDBVnA>	NWjNR3lpOjRzN{ewNVI>
H1299/ICAM-3	NXP6TWk2TnWwY4Tpc44hSXO\|YYm=	M4\DWFEwPS9zMD:yNOKhdk1?	MW[5OkBp		M{HnRYlv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[ZMuOyxiODygPUwh[W6mIGDBVnA>	M2nWblI1OTd5MEGy
W1	NXzuO5RGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTBwMECzNkDPxE1?	M1HVT\|I1OTRyMUe2
W1VR	MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDjOZpKSzVyPUCuNFU3KM7:TR?=	NXn2OIFpOjRzNECxO\|Y>
K562	NFjNZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrPTWM2OD1yLkCzNkDDuSByLkCwNUAh\|ryP	MWGyOFE{PTl\|Nx?=
K562/ADR	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLhWYpKSzVyPUOuNlYyKMLzIECuOFEzKM7:TR?=	NYDtZmdrOjRzM{W5N\|c>
K562	MkPuRZBweHSxc3nzJGF{e2G7	M4XYTVAvOyEQvF2=	M1\YcVI1KGh?		M2jKS4lv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl?	M2LmWFI1OTN3OUO3
K562/ADR	MUjBdI9xfG:\|aYOgRZN{[Xl?	NILV[5U{KM7:TR?=	NVvWPI41OjRiaB?=		M1n3XYlv\HWlZYOgZZBweHSxc3nz	MV6yOFE{PTl\|Nx?=
A549	NInHcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml[yTWM2OD1yLkGwJOKyKDBwMEOg{txO	M4D3O\|I{QTdzMEe1
K562	NELZOWtE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MXSzMlc26oDVNkFCpI5O	MX23NuKhcMLi		NVzXTms4cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	MV6yN\|g4PzJ{Mx?=
lucena	M4noXWNmdGxiVnnhZoltcXS7IFHzd4F6	M3rKNlMvPzYkgKO2NOKhdk1?	M2nzW\|czyqCqwrC=		MmnJco8h\W[oZXP0	NXvLbWI4OjN6N{eyNlM>
FEPS	M4Hld2NmdGxiVnnhZoltcXS7IFHzd4F6	NWP5SmIxOy55NfMAl\|YxyqCwTR?=	NGjnT3M4OsLiaNMg		NWfnZ4JNdm9iZX\m[YN1	NGLxOJUzOzh5N{KyNy=>
A2780	NVLLUGZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\3TWM2OD1\|LkWgcW0>	MVOyN\|gzQTJyMx?=
ACHN	M3OwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{j0WGlEPTB:MD6xJI1O	NX\wcWxLOjN6MkmyNFM>
U-937	M3[xd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjVSmFKSzVyPEO0JI5O	M{HjcVI{QDJ7MkCz
Jurkat	NWnnd3NVSXCxcITvd4l{KEG\|c3H5	M{iyW\|XDqM7:Zz;tcOKh	MYSyOEBp		M3\Cc4lv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl?	MUiyN\|gyODRyOR?=
Jurkat	M4j3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;TT40yPcLizsznM41tyqB?	MnKzNlQhcA>?		NWr0[HN1[XK{ZYP0JGp2emujdDDj[YxteyCrbjDHNk9OKHCqYYPl	NYC4SIw2OjN6MUC0NFk>
Hep-2	NUHaNZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn70TWM2OD1yLkC0xtExNjBzIN88US=>	MnHuNlM4QDB2MkS=
Hep-2/v	M4LBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvtVVdKSzVyPUGuPOKyOC5{MDFOwG0>	MmDkNlM4QDB2MkS=
SGC-7901	NXzy[nh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1[2eFAuOTBizsznM41t	M4rFd\|I1NzR6L{eyJIg>		NYf6[2ZRcW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz	MnLLNlM4PDN3N{K=
SGC-7901/VCR	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorlNE0yOCEQvHevcYw>	MWGyOE81QC95MjDo		MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	NHLVZXYzOzd2M{W3Ni=>
SGC-7901	MVPBdI9xfG:\|aYOgRZN{[Xl?				NH:0O3RqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7	M3\WOFI{PzR\|NUey
SGC-7901/VCR	NXziPGdiSXCxcITvd4l{KEG\|c3H5				MWDpcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6	M1LEbFI{PzR\|NUey
KB-3-1	M{XJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTFwNk[gxtEhOC5zNkKg{txO	NF\afIUzOzZ5M{S0OS=>
KB-C2	NWDsXJI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXLdpVyUUN3ME2yNFIvPTZiwsGgOFIvPDhzIN88US=>	MkHtNlM3PzN2NEW=
KB-3-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPvTWM2OD1zLkK2JOKyKDBwMEK3JO69VQ>?	M{n4T\|I{Pjd\|NES1
KB-V1	NV:0bmd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTJyOD64OUDDuSB{MD60JO69VQ>?	Mnn5NlM3PzN2NEW=
HEK293/pcDNA3.1	M3zxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXOTWM2OD1{ND6xJOKyKDBwMkC0JO69VQ>?	NWjOOodwOjN4N{O0OFU>
HEK293/ABCB1	M1:4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvoTWM2OD1\|NUGyMlghyrFiM{e4MlM6OSEQvF2=	M2KwOVI{Pjd\|NES1
A549/EGFP	NHXwTnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjsfWJ6OC5yMT2xNFAxKM7:TR?=			M{DoU2lEPTB;OE[uO{DDuSB{OT6xJO69VQ>?	NEXUOJQzOzZ\|NEK4Ni=>
A549/Slug	MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\zXlAvODFvMUCwNEDPxE1?			MmrGTWM2OD17LkegxtEhOy5zIN88US=>	MYqyN\|Y{PDJ6Mh?=
JFCR39	MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUOxJOK2VQ>?	M4mzTlI1KGh?	M32ySmROW09?	MnHhcYFzc2WmbImgbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiR{KvUUBxcGG\|ZTDj[Yxtew>?	MknqNlM2QTh{N{[=
A549	NHGzWXdHfW6ldHnvckBCe3OjeR?=	M{CxOlExOCCwTR?=	NHXUUlAyPiCq	NFr1bGtFVVOR	NIjVdY9t\WGmczD0c{BiKGyxc4Ogc4YhdWmlcn;0eYJ2dGW\|	NYq3d3FXOjN3OUiyO\|Y>
SGC7901	NUTBfmhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEG5b\|FKSzVyPUGuNlbjiIoEsfMAjVAvOTFizsznM41t	MYKyN\|U3PDR6Mh?=
SGC7901/LV-NC	NYi3WGxZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmW2TWM2OD1zLke35qCKyrIkgJmwMlE3KM7:Zz;tcC=>	NEH3WWgzOzV4NES4Ni=>
SGC7901/LV-SGO1	NIPUVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fLdWlEPTB;ND6zOwKBkcLz4pEJNE4{PyEQvHevcYw>	NXHEOpFTOjN3NkS0PFI>
SGC7901/VCR	M2jVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFy2T5FKSzV\|PUKwMlU{6oDLwsJihKkyNjl4IN88[{9udA>?	M3vMdlI{PTZ2NEiy
SGC7901/VCR-NC	NWLjV4NbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTF7Lki25qCKyrIkgJmyMlAyKM7:Zz;tcC=>	MX:yN\|U3PDR6Mh?=
SGC7901/VCR-si-SGO1	M4nLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfMUVNKSzVyPU[uNVjjiIoEsfMAjVEvODNizsznM41t	M{DWdVI{PTZ2NEiy
SGC7901/ADR	NGrTO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3iyc2lEPTB;Nz64OgKBkcLz4pEJNE43PCEQvHevcYw>	NUPDW4lCOjN3NkS0PFI>
SGC7901/ADR-NC	MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRThwOURihKnDueLCiUCuOlgh\|rypL33s	NWDVR5B2OjN3NkS0PFI>
SGC7901/ADR-si-SGO1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVS1[\|A{UUN3ME2zMlQ36oDLwsJihKkxNjJ7IN88[{9udA>?	Ml7xNlM2PjR2OEK=
SH-SY5Y	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfJb\|R7OC5yMEGtNVAh\|ryP	NVrqUI13OjRiaB?=		MoXnTWM2OD1yLkGxN:KyOC5yMUKg{txO	NGn5VnMzOzF{OUC2OS=>
SH-SY5Y	NE\ST4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnniNE4xODFvMUCg{txO	M336RlQ5KGh?		NHTmRmdKSzVyPUCuNFc5yrFyLkCwPUDPxE1?	NEjoZ2EzOzF{OUC2OS=>
SH-SY5Y	NUjGUVlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHNVnBCOC5yMEGtNVAh\|ryP	NIn6W3Q4OiCq		M{XwW2lEPTB;MD6wOVHDuTBwMEC4JO69VQ>?	Mn3BNlMyOjlyNkW=
SH-SY5Y	NX7jTppiSXCxcITvd4l{KEG\|c3H5	NGX2NmoxNjFizszN	NIfFcGcxNTJ2IHi=		M2[4PIlv\HWlZYOgZZBweHSxc3nzJI9nKFOKLWPZOXkh[2WubIOg[o9tdG:5aX7nJINmdGxiY4njcIUh[XK{ZYP0JIF1KHSqZTDHNk9OKHCqYYPl	NELvS24zOzF{OUC2OS=>
SH-SY5Y	NF24[oZCeG:ydH;zbZMhSXO\|YYm=	MnfXNE4yKM7:TR?=	M2nIWFAuOjRiaB?=		MoHubY5lfWOnczDtbZRwfGmlIHHydoV{fMLi	NGGzNpczOzF{OUC2OS=>

... Click to View More Cell Line Experimental Data

体内研究

Vincristine 按3 mg/kg剂量单独腹腔注射给药携带双侧皮下移植瘤RH12或RH18的小鼠，平均生长延迟120天和52天以上，且再植指数分别为0.06％和5％。^[5] Vincristine 处理小鼠，通过宿主细胞介导的血管效应及直接的微管蛋白介导的的细胞毒性作用而对皮下结肠38肿瘤起作用。Vincristine (5 mg/kg) 降低肿瘤血流量，降低近75%。^[6]

细胞实验：^[1]	+ 展开 Cell lines: B16 黑色素瘤细胞 Concentrations: 10 nM Incubation Time: 3 天 Method: 细胞按5 × 10⁴ cells/mL的浓度接种在含2 mL培养基的35-mm 实验板上，在37°C下含5% CO₂ 和95% 空气的环境下生长24小时。然后使用有或无10 nM药物的新鲜培养基更换原来的培养基，继续增殖3天。使用胰蛋白酶和EDTA将细胞分离后，每天使用库氏计数器完成细胞计数 (Only for Reference)
动物实验：^[5]	+ 展开 Animal Models: 携带人类横纹肌肉瘤移植瘤Rh12的鼠 Formulation: 水溶液 Dosages: 3 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

+ 展开

溶解度 (25°C)

体外	DMSO	100 mg/mL (108.33 mM)
	Water	60 mg/mL (65.0 mM)
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： Saline	30 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Vincristine sulfate SDF

分子量	923.04
化学式	C₄₆H₅₈N₄O₁₄S
CAS号	2068-78-2
稳定性	3 years -20°C powder
稳定性	2 years -80°C in solvent
别名	Leurocristine

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2018-11-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03571321	Not yet recruiting	Acute Lymphoblastic Leukemia\|ALL Childhood\|ALL	University of Chicago\|Incyte Corporation	September 5 2019	Phase 1
NCT03349281	Recruiting	Refractory Acute Lymphoblastic Leukemia\|Relapsed Acute Lymphoblastic Leukemia	Julio Barredo\|Takeda\|University of Miami	March 2019	Phase 1
NCT03710772	Not yet recruiting	CD20 Positive\|Mantle Cell Lymphoma	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	January 31 2019	Phase 2
NCT03613428	Not yet recruiting	Acute T Cell Leukemia	Sichuan University	December 1 2018	Phase 1\|Phase 2
NCT03742258	Not yet recruiting	Diffuse Large B-Cell Lymphoma\|Diffuse Large B-Cell Lymphoma Activated B-Cell Type\|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type\|Diffuse Large B-Cell Lymphoma Not Otherwise Specified\|High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements\|High Grade B-Cell Lymphoma Not Otherwise Specified\|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma	Northwestern University\|National Cancer Institute (NCI)	December 29 2018	Phase 1
NCT03704714	Not yet recruiting	Aggressive Non-Hodgkin Lymphoma\|B-Cell Non-Hodgkin Lymphoma\|CD20 Positive\|Diffuse Large B-Cell Lymphoma Unclassifiable\|Intravascular Large B-Cell Lymphoma\|Primary Mediastinal (Thymic) Large B-Cell Lymphoma\|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma\|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	Northwestern University\|Bristol-Myers Squibb (BMS)\|National Cancer Institute (NCI)	November 8 2018	Phase 1\|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?
回答：
According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

研究领域

产品类型

Vincristine sulfate

客户使用Selleck该产品发表文献14篇：

客户使用该产品的2个实验数据：

产品安全说明书

Microtubule Associated抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Vincristine sulfate SDF

计算器

摩尔浓度计算器

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2018-11-16)

技术支持

常见问题及建议解决方法

Microtubule Associated Signaling Pathway Map

相关Microtubule Associated产品